BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20472848)

  • 1. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.
    Mhawech-Fauceglia P; Herrmann FR; Rai H; Tchabo N; Lele S; Izevbaye I; Odunsi K; Cheney RT
    Am J Clin Pathol; 2010 Jun; 133(6):899-908. PubMed ID: 20472848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ER+ /PR+ /TFF3+ /IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases.
    Mhawech-Fauceglia P; Yan L; Liu S; Pejovic T
    Histopathology; 2013 Jun; 62(7):976-85. PubMed ID: 23570281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
    Li C; Zota V; Woda BA; Rock KL; Fraire AE; Jiang Z; Lu D; Xu B; Dresser K; Lutman CV; Fischer AH
    Mod Pathol; 2007 Dec; 20(12):1263-8. PubMed ID: 17885673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.
    Mhawech-Fauceglia P; Wang D; Kesterson J; Syriac S; Clark K; Frederick PJ; Lele S; Liu S
    PLoS One; 2011 Mar; 6(3):e18066. PubMed ID: 21448288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
    Al-Hussaini M; Stockman A; Foster H; McCluggage WG
    Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes.
    Lu L; Wang S; Zhu Q; Qu Y; Gu W; Ning Y; Chen X; Wang Y
    Pathol Res Pract; 2018 Aug; 214(8):1087-1094. PubMed ID: 29866423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma.
    Kommoss F; Faruqi A; Gilks CB; Lamshang Leen S; Singh N; Wilkinson N; McCluggage WG
    Am J Surg Pathol; 2017 Feb; 41(2):161-170. PubMed ID: 27776011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
    Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
    J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
    Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
    Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study.
    Athanassiadou P; Athanassiades P; Grapsa D; Gonidi M; Athanassiadou AM; Stamati PN; Patsouris E
    Int J Gynecol Cancer; 2007; 17(3):697-704. PubMed ID: 17504383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-II mRNA-binding protein 3 immunocytochemical expression in direct endometrial brushings: Possible diagnostic help in endometrial cytology.
    Norimatsu Y; Yanoh K; Maeda Y; Irino S; Hirai Y; Fulciniti F; Kobayashi TK
    Cytopathology; 2019 Mar; 30(2):215-222. PubMed ID: 30614088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic and immunohistochemical analyses of endometrial carcinomas: experiences from endometrial biopsies in 358 consultation cases.
    Wei JJ; Paintal A; Keh P
    Arch Pathol Lab Med; 2013 Nov; 137(11):1574-83. PubMed ID: 24168495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the endometrial, cervicovaginal and anorectal microbiota in post-menopausal women with endometrioid and serous endometrial cancers.
    Gressel GM; Usyk M; Frimer M; Kuo DYS; Burk RD
    PLoS One; 2021; 16(11):e0259188. PubMed ID: 34739493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serous versus high-grade endometrioid endometrial carcinoma: immunohistochemistry of RFP is not useful for differentiation.
    Ussakli C; Usubutun A; Dincer N; Dolgun A; Bülbül D; Isikdogan Z; Haberal N; Ozen O; Tezel GG
    Pol J Pathol; 2016; 67(3):221-227. PubMed ID: 28155970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
    Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
    Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
    McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
    Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.